Prostate stem cell antigen（PSCA） is a cell-membrane glycoprotein consisting of 123 amino acids and highly expressed in the prostate,but there have been few reports on the relationship between rs2294008 of PSCA and p...Prostate stem cell antigen（PSCA） is a cell-membrane glycoprotein consisting of 123 amino acids and highly expressed in the prostate,but there have been few reports on the relationship between rs2294008 of PSCA and prostate cancer in the literature.Therefore,we evaluated the association between rs2294008 and the risk of prostate cancer.A total of 240 prostate cancer patients and 306 controls（patients with benign prostatic hyperplasia） were enrolled.Genotype analysis of rs2294008 of PSCA was performed using PCR.Logistic regression analysis was performed according to the genotype of PSCA rs2294008.We found that CT and TT genotypes were associated with an insignificant risk of prostate cancer compared with the CC genotype（P= 0.627 and 0.397,respectively）.In addition,there was no significant difference in rs2294008 according to clinicopathological parameters,such as age,Gleason score,prostate-specific antigen（PSA）,stage,and metastasis in prostate cancer（P 〉 0.05 for each）.Age,Gleason score,PSA,pathologic stage,and metastasis did not modify the association between PSCA and the risk of prostate cancer（each P 〉 0.05 for each）.Taken together,the genetic polymorphism of PSCA rs2294008 was not associated with the risk of prostate cancer.Our results suggest that rs2294008 may not play a role in prostate carcinogenesis.展开更多
This study was designed to identify clinical predictors of favorable pathology and biochemical recurrence （BCR） in patients with intermediate-risk prostate cancer （IRPCa）. Between 2006 and 2012, clinicopathologica...This study was designed to identify clinical predictors of favorable pathology and biochemical recurrence （BCR） in patients with intermediate-risk prostate cancer （IRPCa）. Between 2006 and 2012, clinicopathological and oncological data from 203 consecutive men undergoing robot-assisted radical prostatectomy （RARP） for IRPCa were reviewed in a single-institutional retrospective study. Favorable pathology was defined as Gleason score 〈6 and organ-confined cancer as detected by surgical pathology. Logistic regression analysis was used to determine predictive variables of favorable pathology, and the Kaplan-Meier and multivariate Cox regression model were used to estimate BCR-free survival after RARP. Overall, 38 patients （18.7%） had favorable pathology after RARP. Lower quartile prostate-specific antigen density （PSAD） was associated with favorable pathology compared to the highest quartile PSAD after adjusting for preoperative PSA, clinical stage and biopsy Gleason score （odds ratio, 5.42; 95% confidence interval, 1.01-28.97; P = 0.048）. During a median 37.8 （interquartile range, 24.6-60.2） months of follow-up, 66 patients experienced BCR. There were significant differences with regard to BCR free survival by PSAD quartiles （log rank, P = 0.003）. Using a multivariable Cox proportion hazard model, PSAD was found to be an independent predictor of BCR in patients with IRPCa after RARP （hazard ratio, 4.641; 95% confidence interval, 1.109-19.417; P = 0.036）. The incorporation of the PSAD into risk assessments might provide additional prognostic information and identify some patients in whom active surveillance would be appropriate in patients with IRPCa.展开更多
基金supported by the research grant of Chungbuk National University in 2014
文摘Prostate stem cell antigen（PSCA） is a cell-membrane glycoprotein consisting of 123 amino acids and highly expressed in the prostate,but there have been few reports on the relationship between rs2294008 of PSCA and prostate cancer in the literature.Therefore,we evaluated the association between rs2294008 and the risk of prostate cancer.A total of 240 prostate cancer patients and 306 controls（patients with benign prostatic hyperplasia） were enrolled.Genotype analysis of rs2294008 of PSCA was performed using PCR.Logistic regression analysis was performed according to the genotype of PSCA rs2294008.We found that CT and TT genotypes were associated with an insignificant risk of prostate cancer compared with the CC genotype（P= 0.627 and 0.397,respectively）.In addition,there was no significant difference in rs2294008 according to clinicopathological parameters,such as age,Gleason score,prostate-specific antigen（PSA）,stage,and metastasis in prostate cancer（P 〉 0.05 for each）.Age,Gleason score,PSA,pathologic stage,and metastasis did not modify the association between PSCA and the risk of prostate cancer（each P 〉 0.05 for each）.Taken together,the genetic polymorphism of PSCA rs2294008 was not associated with the risk of prostate cancer.Our results suggest that rs2294008 may not play a role in prostate carcinogenesis.
文摘This study was designed to identify clinical predictors of favorable pathology and biochemical recurrence （BCR） in patients with intermediate-risk prostate cancer （IRPCa）. Between 2006 and 2012, clinicopathological and oncological data from 203 consecutive men undergoing robot-assisted radical prostatectomy （RARP） for IRPCa were reviewed in a single-institutional retrospective study. Favorable pathology was defined as Gleason score 〈6 and organ-confined cancer as detected by surgical pathology. Logistic regression analysis was used to determine predictive variables of favorable pathology, and the Kaplan-Meier and multivariate Cox regression model were used to estimate BCR-free survival after RARP. Overall, 38 patients （18.7%） had favorable pathology after RARP. Lower quartile prostate-specific antigen density （PSAD） was associated with favorable pathology compared to the highest quartile PSAD after adjusting for preoperative PSA, clinical stage and biopsy Gleason score （odds ratio, 5.42; 95% confidence interval, 1.01-28.97; P = 0.048）. During a median 37.8 （interquartile range, 24.6-60.2） months of follow-up, 66 patients experienced BCR. There were significant differences with regard to BCR free survival by PSAD quartiles （log rank, P = 0.003）. Using a multivariable Cox proportion hazard model, PSAD was found to be an independent predictor of BCR in patients with IRPCa after RARP （hazard ratio, 4.641; 95% confidence interval, 1.109-19.417; P = 0.036）. The incorporation of the PSAD into risk assessments might provide additional prognostic information and identify some patients in whom active surveillance would be appropriate in patients with IRPCa.
